替吉奥胶囊联合同步放疗治疗晚期胃癌的临床研究

《替吉奥胶囊联合同步放疗治疗晚期胃癌的临床研究》由会员上传分享，免费在线阅读，更多相关内容在应用文档-天天文库。

1、替吉奥胶囊联合同步放疗治疗晚期胃癌的临床研究穆克代斯•伊力亚斯巴尔夏古丽•扎比胡拉伊斯刊达尔•阿布力米提新疆医科大学附属肿瘤医院胸腹放疗科目的观察替吉奥胶囊联合同步放疗治疗晚期胃癌的临床疗效和安全性。方法将92例晚期胃癌患者随机分为对照组46例和试验组46例。对照组予以同步放疗,每周5次;试验组在对照组治疗的基础上，予以40mg*m-2替吉奥，早晚各1次，门服，连服14d后停药7d。2组患者一个疗程21d，共治疗2个疗程。比较2组患者的临床疗效和药物不良反应的发生情况。结果治疗后，试验组和对照组的总有效率分别为67.39%（31例/46例）和45.65%（21例/46

2、例），1年存活率分别为69.57%（32例/46例）和45.65%（21例/46例），差异均有统计学意义（均P〈0.05）。试验组和对照组的IIP级恶心呕吐发生率分别为2.17%和15.22%,I11级转氨酶升高发生率分别为17.39%和36.96%，IIP级白细胞减少发生率分别为10.87%和39.13%，差异均有统计学意义（均P<0.05）。结论替吉奥胶囊联合同步放疗治疗晚期胃癌的临床疗效显著，且安全性较好。关键词：替吉奥胶囊;放疗;胃癌;安全性;穆克代斯•伊力亚斯（1976-）,女，主治医师，主要从事胸腹肿瘤放射治疗工作伊斯刊达尔•阿布力米提，主任医师，生导师M

3、P:18911581182E~mai1:shaowen_zhang@126.com2017-06-21ClinicaltrialoftegafurgimeracilandoteracilpotassiumcapsulescombinedwithradiotherapyinthetreatmentofadvancedgastriccancerMUKEDAISI•YiliyasiBAERXIAGULI.ZabihulaYISIKANDAER•AbulimitiDepartmentofThoracicandAbdominalRadiation,AffiliatedTumor

4、Hospital，XinjiangMedicalUniversity;Abstract：ObjectiveToobservetheclinicalefficacyandsafetyoftegafurgimeracilandoteracilpotassiumcapsulescombinedwithradiotherapyinthetreatmentofadvancedgastriccancer.MethodsAtotalof92patientswithadvancedgastriccancerwererandomlydividedintocontrolgroupandt

5、reatmentgroupwith46casespergroup.Controlgroupreceivedradiotherapy,fivetimesaweek.Treatmentgroupwasgiven40mg•m-2tegafurgimeracilandoteracilpotassiumcapsules,everymorningandnight,orallyfor14dayandstopfor7days,onthebasisofcontrolgroup.Twogroupsweretreatedfor2cycleswith21dpercycle.Theclinic

6、alefficacyandadversedrugreactionswerecomparedbetweentwogroups.ResultsAftertreatment，thetotaleffectiveratesinthetreatmentandcontrolgroupswere67.39%(31cases/46cases)and45.65%(21cases/46cases)，the1-yearsurvivalratesinthetreatmentandcontrolgroupswere69.57%(32cases/46cases)and45.65%(21cases/

7、46cases)，thedifferenceswerestatisticallysignificant(allP<0.05).Inthetreatmentanclcontrolgroups,theincidencesofnauseaandvomitingwithgradeIII-IVwere2.17%and15.22%,theincidencesofincreasingtransaminasewithgradeI-IIwere17.39%and36.96%,theincidencesofleukopeniawithgradeIII-IVwere10.